Advanced Search
XU Wenjing, WANG Pei, MA Yueshi, GAO Liping. Clinical Features and Prognosis of 60 Cases of HIV-negative Plasmablastic Lymphomas Patients[J]. Cancer Research on Prevention and Treatment, 2021, 48(4): 375-380. DOI: 10.3971/j.issn.1000-8578.2021.20.0878
Citation: XU Wenjing, WANG Pei, MA Yueshi, GAO Liping. Clinical Features and Prognosis of 60 Cases of HIV-negative Plasmablastic Lymphomas Patients[J]. Cancer Research on Prevention and Treatment, 2021, 48(4): 375-380. DOI: 10.3971/j.issn.1000-8578.2021.20.0878

Clinical Features and Prognosis of 60 Cases of HIV-negative Plasmablastic Lymphomas Patients

More Information
  • Corresponding author:

    GAO Liping, E-mail: 13310240092@163.com

  • Received Date: July 21, 2020
  • Revised Date: December 01, 2020
  • Available Online: January 12, 2024
  • Objective 

    To investigate the clinical features and prognosis of HIV-negative plasmablastic lymphoma (PBL) patients.

    Methods 

    We collected HIV-negative PBL cases reported in our hospital and other literatures from online databases from January 1, 1997 to March 30, 2020. The data of clinical features, molecular pathology, treatment and prognosis were summarized and analyzed.

    Results 

    We included 60 PBL patients, average age was 53.06±14.36 years, and most of them had relatively high Ann Arbor stage and Ki-67 expression. The average OS was 13.48±13.21 m. Kaplan-Meier curve revealed Ann Arbor stage, IPI index (3-5), B symptoms and CR in initial treatment were significantly related with patients' survival. Cox regression analysis indicated that the Ann Arbor stage and IPI index were the independent prognostic factors for patients' survival. Conclusion HIV-negative PBL mostly occurs in the middle-age and elderly patients, with advanced diagnosis stage and rapid tumor proliferation.

    Combination 

    chemotherapy is the main treatment, while the therapeutic response and OS might be heterogeneous, the prognosis of most patients would be poor. The stage and IPI index are significantly related to the prognosis.

  • [1]
    Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. doi: 10.1182/blood-2016-01-643569
    [2]
    Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma[J]. Blood, 2015, 125(15): 2323-2330. doi: 10.1182/blood-2014-10-567479
    [3]
    Reardon S. Infections reveal inequality between the sexes[J]. Nature, 2016, 54(7608): 447.
    [4]
    Liu M, Liu B, Liu B, et al. Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases[J]. Oncol Rep, 2015, 33(4): 1615-1620. doi: 10.3892/or.2015.3808
    [5]
    蓝三春, 谢婧, 朱搏宇, 等. 乙型肝炎病毒相关浆母细胞淋巴瘤1例并文献复习[J]. 军事医学, 2018, 42(1): 77-78, 80. https://www.cnki.com.cn/Article/CJFDTOTAL-JSYX201801031.htm

    Lan SC, Xie J, Zhu BY, et al. A case of hepatitis B virus-related plasmablastic lymphoma and literature review[J]. Jun Shi Yi Xue, 2018, 42(1): 77-78, 80. https://www.cnki.com.cn/Article/CJFDTOTAL-JSYX201801031.htm
    [6]
    Sarode SC, Sarode GS, Patil A. Plasmablastic lymphoma of the oral cavity: a review[J]. Oral Oncol, 2010, 46(3): 146-153. doi: 10.1016/j.oraloncology.2009.12.009
    [7]
    Lopez A, Abrisqueta P. Plasmablastic lymphoma: current perspectives[J]. Blood Lymphat Cancer, 2018, 8: 63-70. http://www.researchgate.net/publication/328072487_Plasmablastic_lymphoma_current_perspectives/download
    [8]
    Bhatt R, Desai DS. Plasmablastic Lymphoma[M/OL]. StatPearls Publishing[2020-8-24]. https://www.ncbi.nlm.nih.gov/books/NBK532975/
    [9]
    Castillo JJ, Winer ES, Stachurski D, et al. HIV-negative plasmablastic lymphoma: not in the mouth[J]. Clin Lymphoma Myeloma Leuk, 2011, 11(2): 185-189. doi: 10.1016/j.clml.2011.03.008
    [10]
    Castillo JJ, Winer ES, Stachurski D, et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma[J]. Leuk Lymphoma, 2010, 51(11): 2047-2053. doi: 10.3109/10428194.2010.516040
    [11]
    Akce M, Chang E, Haeri M, et al. Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma[J]. Case Rep Hematol, 2016, 2016: 3598547. http://www.ncbi.nlm.nih.gov/pubmed/27957358
    [12]
    范舟, 李基炜, 易平勇, 等. 5例浆母细胞淋巴瘤临床病例分析和文献回顾[J]. 肿瘤药学, 2018, 8(1): 124-128. doi: 10.3969/j.issn.2095-1264.2018.01.29

    Fan Z, Li JW, Yi PY, et al. Case Report on 5 Plasmablastic Lymphoma Patients and Literature Review by Retrospective Analysis[J]. Zhong Liu Yao Xue, 2018, 8(1): 124-128. doi: 10.3969/j.issn.2095-1264.2018.01.29
    [13]
    Yan M, Dong Z, Zhao F, et al. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab[J]. Eur J Haematol, 2014, 93(1): 77-80. doi: 10.1111/ejh.12286
    [14]
    Holderness BM, Malhotra S, Levy NB, et al. Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia[J]. J Clin Oncol, 2013, 31(12): e197-199. doi: 10.1200/JCO.2012.46.9593
    [15]
    Pretscher D, Kalisch A, Wilhelm M, et al. Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy[J]. Ann Hematol, 2017, 96(6): 967-970. doi: 10.1007/s00277-016-2904-7
    [16]
    Mine S, Hishima T, Suganuma A, et al. Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets[J]. Sci Rep, 2017, 7(1): 10188. doi: 10.1038/s41598-017-10684-5
    [17]
    Koenig G, Stevens TM, Peker D. Plasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapy[J]. Histopathology, 2015, 67(6): 930-932. doi: 10.1111/his.12718
    [18]
    Yanamandra U, Sahu KK, Jain N, et al. Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings[J]. Ann Hematol, 2016, 95(10): 1715-1717. doi: 10.1007/s00277-016-2732-9
    [19]
    Laurent C, Fabiani B, Do C, et al. Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients[J]. Haematologica, 2016, 101(8): 976-984. doi: 10.3324/haematol.2016.141978
    [20]
    Cattaneo C, Finel H, McQuaker G, et al. Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: the European Society for Blood and Marrow Transplantation experience[J]. Biol Blood Marrow Transplant, 2015, 21(6): 1146-1147. doi: 10.1016/j.bbmt.2015.03.008
    [21]
    Elyamany G, Al Mussaed E, Alzahrani AM. Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions[J]. Adv Hematol, 2015, 2015: 315289. http://www.ncbi.nlm.nih.gov/pubmed/27110244
  • Related Articles

    [1]HE Jiawei, CAO Longnyu, TANG Mengyuan, CUI Hongquan. Causal Relationships Between Immune Cells and Risk of Gastric Cancer: A Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 172-176. DOI: 10.3971/j.issn.1000-8578.2025.24.0438
    [2]WU Tong, GAO Fei, TENG Fei, ZHANG Qiaoli. Genetic Determinants of Immune Cells and Hepatocellular Carcinoma Risk: A Bioinformatics and Bidirectional Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2025, 52(1): 42-51. DOI: 10.3971/j.issn.1000-8578.2025.24.0562
    [3]YUAN Chendong, SHU Xufeng, WANG Xiaoqiang, JIE Zhigang. Relationship Between High-Density Lipoprotein Cholesterol and Colorectal Cancer—A Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 847-851. DOI: 10.3971/j.issn.1000-8578.2024.24.0153
    [4]GONG Wanli, HOU Yaqi, WANG Yue, LI Yuan, QI Rongxuan, YU Qi, ZHANG Juan. Immune Cell-Mediated Effect of Lipid Profile on Colorectal Cancer: A Two-Step, Two-Sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 831-839. DOI: 10.3971/j.issn.1000-8578.2024.24.0284
    [5]LIU Jingting, ZHOU Yawei, KONG Lingguo, WANG Qiandan, SU Tianxiong, PEI Jianying, LI Yan. Causal Association Between Immune Cells and Cervical Cancer: A Two-Sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(9): 772-778. DOI: 10.3971/j.issn.1000-8578.2024.24.0037
    [6]WANG Yuanhang, SONG Zhiyuan, LU Ping, ZHANG Min. Analysis of Association Between Immune Cells and Breast Cancer Based on Two-sample Mendelian Randomization Method[J]. Cancer Research on Prevention and Treatment, 2024, 51(5): 348-352. DOI: 10.3971/j.issn.1000-8578.2024.23.1125
    [7]LIU Longjiao, YAO Yufeng. Circulating Inflammatory Proteins in Relation to Risk of Breast Cancer: A Two-sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(5): 342-347. DOI: 10.3971/j.issn.1000-8578.2024.23.1344
    [8]WEI Wei, LIU Ming, XU Jianguo, GAO Ya, SHEN Caiyi, TIAN Jinhui. Causal Relationship Between Acromegaly and Colon Cancer: A Two-sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1209-1213. DOI: 10.3971/j.issn.1000-8578.2023.23.0507
    [9]WANG Mengyuan, XU Hengmin, WANG Jingxuan, PAN Kaifeng, LI Wenqing. Mendelian Randomization Analysis of Research on Risk Factors for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(5): 470-476. DOI: 10.3971/j.issn.1000-8578.2023.22.1411
    [10]Xin-ying ZHOU, Hu ZHANG, Hai-yan DAI. Mendelian randomization analysis of the correlation between interleukin and the risk of gynecological tumors[J]. Cancer Research on Prevention and Treatment. DOI: 10.3971/j.issn.1000-8578.20240994
  • Cited by

    Periodical cited type(13)

    1. 吴杨,隋雨桐,李斌鹏,韩路拓,姜家康. 激酶/转录因子信号通路调控肺癌机制及中医药干预的研究进展. 世界中医药. 2025(01): 142-147+154 .
    2. 曹家瑞,冯博,马纯政,陈伟霞,喻江凡,曹莎莎,张振予,欧阳文慧. 中医药调控JAK/STAT信号通路干预肺癌的机制研究进展. 中国实验方剂学杂志. 2025(09): 265-276 .
    3. 梁帅,尹怡,刘湘花,汪保英,骆文龙,龙云凯,任振杰,王祥麒. 升降理肺消瘤汤对Lewis肺癌小鼠免疫炎性反应和JAK2/STAT3信号通路的影响. 辽宁中医药大学学报. 2024(04): 27-32 .
    4. 张彩蝶,靳艳,张德德. 润肺益肾饮对肺癌荷瘤大鼠的抑瘤作用和肿瘤免疫微环境的影响. 天津医药. 2024(04): 362-366 .
    5. 孙喜,王召路,贾谨睿,王梦洋,孙润卓,王鹏,史新娥. 虫草素及其在生猪养殖中的应用. 畜牧兽医杂志. 2024(04): 1-7 .
    6. 兰春燕,杨小兰,贺雪峰,赵丹,杨海燕. 甘草苷对胃癌荷瘤小鼠免疫功能的调节作用及机制研究. 中国药房. 2024(15): 1862-1867 .
    7. 张景淇,郭静,陈娅欣,蒲玥衡,向俊杰. 中药调控肺癌相关信号通路研究进展. 中国实验方剂学杂志. 2024(19): 233-244 .
    8. 张孟恩,韩睿,徐超,庞训胜,王世琴. 地顶孢霉培养物在反刍动物生产中的应用研究进展. 中国畜牧杂志. 2024(12): 70-74 .
    9. 高铭,丁美灵,雷紫琴,胡靖文,栾飞,曾南. 荆防败毒散及其中成药制剂研究进展. 中药药理与临床. 2023(05): 112-118 .
    10. 朱亚兰,吕世文,曾晨欣,徐媛青. 苍术素对非小细胞肺癌细胞上皮间质转化的影响及机制研究. 浙江医学. 2023(10): 1013-1018 .
    11. 陈才伟,陈家亮,李华娟,方芳,文方玲. 虫草素调节MAPK/AP-1信号通路对慢性阻塞性肺疾病大鼠肺组织损伤的影响. 临床肺科杂志. 2023(11): 1656-1661 .
    12. 李翔子,王西双,范建伟,杨田野,王丽娟,孙颖,姚景春. 荆防合剂通过抑制JAK2-STAT3信号通路调节荨麻疹小鼠脾脏T淋巴细胞亚群的平衡. 中国中药杂志. 2022(20): 5473-5480 .
    13. 沈栩岚,黄凌霞. 虫草素的抗癌机理. 蚕桑通报. 2022(02): 33-34 .

    Other cited types(4)

Catalog

    Article views (1543) PDF downloads (415) Cited by(17)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return